217 related articles for article (PubMed ID: 31291711)
21. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
23. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
24. Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case-Control Study (KROG 13-06).
Yu JI; Choi DH; Huh SJ; Cho EY; Kim K; Chie EK; Ha SW; Park IA; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Koo JS; Kim JH; Jeong BG; Kim IA; Lee JH; Park W
Clin Breast Cancer; 2015 Oct; 15(5):353-61.e1-2. PubMed ID: 25776197
[TBL] [Abstract][Full Text] [Related]
25. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
26. Gasdermin-B promotes invasion and metastasis in breast cancer cells.
Hergueta-Redondo M; Sarrió D; Molina-Crespo Á; Megias D; Mota A; Rojo-Sebastian A; García-Sanz P; Morales S; Abril S; Cano A; Peinado H; Moreno-Bueno G
PLoS One; 2014; 9(3):e90099. PubMed ID: 24675552
[TBL] [Abstract][Full Text] [Related]
27. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.
Yang F; Zhou X; Miao X; Zhang T; Hang X; Tie R; Liu N; Tian F; Wang F; Yuan J
Breast Cancer Res Treat; 2014 May; 145(1):23-32. PubMed ID: 24687377
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study.
Lin S; Liu C; Tao Z; Zhang J; Hu X
Breast; 2020 Feb; 49():157-164. PubMed ID: 31812891
[TBL] [Abstract][Full Text] [Related]
29. High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy.
Zhang H; Zhao Y; Liu X; Fu L; Gu F; Ma Y
Front Oncol; 2021; 11():724250. PubMed ID: 34631552
[TBL] [Abstract][Full Text] [Related]
30. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
31. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
Ye J; Wang W; Xin L; Owen S; Xu L; Duan X; Cheng Y; Zhang H; Zhang S; Li T; Liu Y
Anticancer Res; 2017 Aug; 37(8):4549-4556. PubMed ID: 28739751
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.
Rahal S; Boher JM; Extra JM; Tarpin C; Charafe-Jauffret E; Lambaudie E; Sabatier R; Thomassin-Piana J; Tallet A; Resbeut M; Houvenaeghel G; Laborde L; Bertucci F; Viens P; Gonçalves A
BMC Cancer; 2015 Oct; 15():697. PubMed ID: 26466893
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological features of indonesian breast cancers with different molecular subtypes.
Widodo I; Dwianingsih EK; Triningsih E; Utoro T; Soeripto
Asian Pac J Cancer Prev; 2014; 15(15):6109-13. PubMed ID: 25124582
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
35. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome.
Yoon NK; Seligson DB; Chia D; Elshimali Y; Sulur G; Li A; Horvath S; Maresh E; Mah V; Bose S; Bonavida B; Goodglick L
Cancer Biomark; 2009; 5(4):215-24. PubMed ID: 19729831
[TBL] [Abstract][Full Text] [Related]
36. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
[TBL] [Abstract][Full Text] [Related]
39. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.
Lai YH; Chen J; Wang XP; Wu YQ; Peng HT; Lin XH; Wang WJ
J Exp Clin Cancer Res; 2017 Jul; 36(1):92. PubMed ID: 28697793
[TBL] [Abstract][Full Text] [Related]
40. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
